You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

27 Items
Other Name(s): Paraplatin AQ® (multiple brands available)
Aug 2016
Other Name(s): Platinol AQ® (multiple brands available)
Aug 2016
Other Name(s): Procytox® (Baxter)
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
Nov 2017
Other Name(s): Cosmegen® (Recordati)
May 2016
Other Name(s): Taxotere® (multiple brands available)
Funding:
New Drug Funding Program
  • Docetaxel - Metastatic Castration-Resistant Prostate Cancer
  • Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
  • Docetaxel - Non-Small Cell Lung Cancer (Second or Subsequent Line)
  • Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
  • Docetaxel - Metastatic Breast Cancer
  • Docetaxel - Hormone Sensitive Prostate Cancer
  • Trastuzumab with First Line Docetaxel - Metastatic Breast Cancer
  • Docetaxel - CYCLDOCE for Early Operable Breast Cancer
  • Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
Nov 2017
Other Name(s): Adriamycin PFS® (multiple brands available)
Nov 2017
Other Name(s): Pharmorubicin PFS® (multiple brands available)
Funding:
New Drug Funding Program
  • Epirubicin - Adjuvant Treatment for Breast Cancer
  • Epirubicin - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
Aug 2016
Other Name(s): Vepesid® (multiple brands available)
Funding:
ODB - General Benefit
  • etoposide - oral capsules
Nov 2017
Other Name(s): Neupogen® (Amgen); Grastofil® (Apotex)
Funding:
ODB - General Benefit
  • filgrastim - Grastofil brand is a general benefit
ODB Limited Use
  • filgrastim - (Neupogen brand) - Pre-Stem Cell Transplant Mobilization: For peripheral blood progenitor cell collection for peripheral stem cell transplant as treatment for malignant disease. Approval for Neupogen 300 mcg and 480 mcg vial format only.
  • filgrastim - (Neupogen brand) For pediatric patients (less than 18 years age) who are unable to achieve the appropriate dose of granulocyte colony-stimulating factor with the formulary listed formats of pre-filled syringes. Approval for Neupogen 300 mcg vial format only.
  • filgrastim - (Neupogen brand) For patients who are unable to use available formats of Grastofil due to a documented latex allergy. Approval for Neupogen 300 mcg and 480 mcg vial format only.
Updated
Jan 2018
Other Name(s): Gemzar® (multiple brands available)
Funding:
New Drug Funding Program
  • Gemcitabine - Carcinoma of Bladder or Urothelium
  • Gemcitabine - Non-Small Cell Lung Cancer (NSCLC)
  • Gemcitabine - Advanced Pancreatic Cancer
Updated
Feb 2018
Other Name(s): Ifex® (multiple brands available)
Aug 2016
Other Name(s): Gleevec® (multiple brands available)
Funding:
Exceptional Access Program
  • iMAtinib - Metastatic Gastrointestinal Stromal Tumours, with specific criteria
  • iMAtinib - Adults with newly diagnosed Ph+ ALL, with specific criteria
  • iMAtinib - Adjuvant Gastrointestinal Stromal Tumours, with specific criteria
ODB - General Benefit (with Therapeutic Notes)
  • iMAtinib - For treatment of Ph+ CML in chronic phase, blast phase or accelerated phase, with specific criteria
Updated
Feb 2018